A dose block-randomized, double-blind, placebo-controlled, single/multiple dosing, dose-escalation clinical phase 1 trial to investigate the safety, tolerability, and pharmacokinetics of DWP09031 after oral administration in healthy male subjects

Trial Profile

A dose block-randomized, double-blind, placebo-controlled, single/multiple dosing, dose-escalation clinical phase 1 trial to investigate the safety, tolerability, and pharmacokinetics of DWP09031 after oral administration in healthy male subjects

Discontinued
Phase of Trial: Phase I

Latest Information Update: 31 May 2017

At a glance

  • Drugs DWP 09031 (Primary)
  • Indications Delirium dementia amnestic cognitive disorders
  • Focus Adverse reactions
  • Sponsors Daewoong Pharmaceutical
  • Most Recent Events

    • 15 Feb 2012 Actual initiation date (18 Jan 2012) added as reported by Korean Clinical Trials Register.
    • 15 Feb 2012 Status changed from not yet recruiting to recruiting as reported by Korean Clinical Trials Register.
    • 15 Feb 2012 Official Title amended as reported by Korean Clinical Trials Register.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top